Fig. 3

Inhibition of METTL3 activity promotes CD4⁺ T-cell activation and suppresses Tfh and Treg cell differentiation in vivo. a Schematic diagram of SRBC immunization and STM2457 administration. STM2457 is a highly potent and selective catalytic inhibitor of MELLT3. b–g Representative dot plots showing the proportions of CD3⁺CD4⁺CD44⁻CD62L⁺ naïve T cells, CD3⁺CD4⁺CD44⁺CD62L⁺ T_CM cells, CD3⁺CD4⁺CD44⁺CD62L⁻ T_EM cells (b), CD4⁺IFN-γ⁺ Th1 cells (c), CD4⁺IL-4⁺ Th2 cells (d), CD4⁺IL-17A⁺ Th17 cells (e), CD4⁺PD1⁺CXCR5⁺ Tfh cells (f), and CD4⁺CD25⁺Foxp3⁺ Treg cells (g) in the spleen of STM2457-treated and DMSO control mice after SRBC challenge; T_CM, central memory T cells; T_EM, effective memory T cells. h Quantification plots of splenic T cells, n = 6. Data are representative of 2 independent experiments. (*p < 0.05, **p < 0.01, ****p < 0.0001, ns, no significance, unpaired two-tailed Student’s t test)